Beige Mouse Model of Disseminated Mycobacterium avium Complex Infection

Author(s):  
M.H. Cynamon ◽  
M.S. DeStefano
1996 ◽  
Vol 38 (5) ◽  
pp. 819-828 ◽  
Author(s):  
E. A. Petersen ◽  
J. B. Grayson ◽  
E. M. Hersh ◽  
R. T. Dorr ◽  
S.-M. Chiang ◽  
...  

Tubercle ◽  
1989 ◽  
Vol 70 (4) ◽  
pp. 257-271 ◽  
Author(s):  
P.R.J. Gangadharam ◽  
V.K. Perumal ◽  
D.C. Farhi ◽  
J. LaBrecque

1996 ◽  
Vol 174 (6) ◽  
pp. 1218-1222 ◽  
Author(s):  
L. E. Bermudez ◽  
K. A. Nash ◽  
M. Petrofsky ◽  
L. S. Young ◽  
C. B. Inderlied

1986 ◽  
Vol 154 (1) ◽  
pp. 194-195 ◽  
Author(s):  
M. A. Bertram ◽  
C. B. Inderlied ◽  
S. Yadegar ◽  
P. Kolanoski ◽  
J. K. Yamada ◽  
...  

2000 ◽  
Vol 44 (10) ◽  
pp. 2895-2896 ◽  
Author(s):  
M. H. Cynamon ◽  
J. L. Carter ◽  
C. M. Shoen

ABSTRACT ABT-773, a new ketolide antimicrobial agent, was evaluated in comparison to clarithromycin (CLA) in vitro against Mycobacterium avium complex (MAC) and in a beige mouse model of disseminated MAC infection. The MICs at which 50 and 90% of the isolates tested were inhibited were 2 and 4 μg/ml, respectively, for CLA and 8 and 16 μg/ml, respectively, for ABT-773. Eight CLA-resistant isolates were found to be resistant to ABT-773 (MICs > 64 μg/ml). In the in vivo study mice were treated with ABT-773 (50, 100, and 200 mg/kg of body weight) or CLA (200 mg/kg). Both ABT-773 (100 and 200 mg/kg) and CLA significantly decreased the viable cell counts in spleens and lungs. ABT-773 (200 mg/kg) and CLA had similar activities in lungs, but the former was more active in spleens.


Sign in / Sign up

Export Citation Format

Share Document